The board of Alkermes plc (NasdaqGS:ALKS) announced the Spin off of Oncology Business of Alkermes plc on November 2, 2022. Transaction will separate its oncology sector from its neuroscience business, creating an independent publicly traded company. Mural Oncology plc is the new independent public company to be established upon the planned separation of Alkermes' oncology business. Caroline J. Loew appointed as the chief executive officer designate of Mural Oncology plc. Richard Pops will continue as Chief Executive Officer and Chairman of Alkermes. Separation of the two businesses would be subject to customary closing conditions and final approval by Alkermes? Board of Directors. As of June 12, 2023, Sarissa claims that Gaynor is solely an oncology specialist and is therefore no longer needed on the Board post-spin of the oncology business. Upon completion of the planned separation, Mural Oncology plc is expected to be a Nasdaq listed company, trading under the ticker symbol MURA. The transaction is expected to be completed in the second half of 2023. As of October 25, 2023, spin off is expected to close in November 2023. As of October 31, 2023, the registration statement has been declared effective, transaction is expected to close on or about November 15, 2023. Morgan Stanley and BofA Securities are serving as financial advisers to Alkermes, and Goodwin Procter LLP and Arthur Cox are serving as its legal counsel. Computershare Trust Company acted as transfer agent.

Alkermes plc (NasdaqGS:ALKS) completed the spin-off of Mural Oncology plc (NasdaqGM:MURA) for approximately ?260 million on November 15, 2023. Upon completion of the separation, each of Alkermes' shareholders received a distribution of one ordinary share of Mural Oncology for every 10 ordinary shares of Alkermes held as of the close of business on November 6, 2023, the record date for the distribution.